<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03581513</url>
  </required_header>
  <id_info>
    <org_study_id>2016YFC1301104</org_study_id>
    <nct_id>NCT03581513</nct_id>
  </id_info>
  <brief_title>Research on STEMI Reperfusion Strategy Based on Microcirculation Function</brief_title>
  <official_title>Research on STEMI Reperfusion Strategy Based on Microcirculation Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The occurrence of heart failure after acute myocardial infarction is affected by many
      factors, among which the myocardial infarction area plays an important role in the occurrence
      of heart failure after acute myocardial infarction as an intervening factor. The
      microcirculation resistance index is an invasive and easy approach. Quantitative analysis of
      the function of coronary microcirculation can reflect the true condition of coronary
      microcirculation impedance. The value of the microcirculatory resistance index correlates
      with the infarct size of patients with acute myocardial infarction and predicts the recovery
      of their left ventricular function. Studies have shown that acute myocardial infarction
      patients with a microcirculatory resistance index &gt;40 after primary PCI predict adverse
      long-term clinical outcomes with higher mortality and heart failure rehospitalization rates.
      Therefore, microcirculatory resistance index is used for post-infarct myocardial
      microcirculatory perfusion. The evaluation of the circulation and exploration of strategies
      and methods for improving myocardial microcirculatory perfusion during interventional
      procedures are practical and feasible. This topic explores the relationship between the
      microcirculatory resistance index and optimal stenting timing in patients with acute
      myocardial infarction, reduces myocardial &quot;re-injury&quot; during reperfusion, establishes a safe
      and effective reperfusion strategy selection process, and reduces the incidence of HF.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of HF or all-cause death or re-myocardial infarction or targeted vessel revascularization within 1 year of AMI</measure>
    <time_frame>1 year</time_frame>
    <description>the MACE events including the prevalence of heart failure or all-cause death or re-myocardial infarction or targeted vessel revascularization will be collected as the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative 90 minutes ECG ST segment fallback</measure>
    <time_frame>90 minutes</time_frame>
    <description>we will compare the differences of the ECG segment fallback at postoperative 60 minutes and 90 minutes among groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peaks of CK, CK-MB and cTnI, area under CK curve</measure>
    <time_frame>3 day</time_frame>
    <description>we will compare the peaks of CK, CK-MB and cTnI among groups, also compare the area under CK curve among groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Echocardiographic indices at 10 days after surgery, 1 month, and 12 months after discharge</measure>
    <time_frame>10 days</time_frame>
    <description>Echocardiographic indices at 10 days after surgery, 1 month, and 12 months after discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial contrast echocardiography results 10 days after surgery and 1 month after discharge</measure>
    <time_frame>1 month</time_frame>
    <description>Myocardial contrast echocardiography results 10 days after surgery and 1 month after discharge</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">880</enrollment>
  <condition>Microcirculatory Perfusion</condition>
  <condition>Microcirculatory Resistance Index</condition>
  <condition>ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>IMR＜40 and defer PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients whose IMR＜40 undergo anticoagulation and antiplatelet therapy for stent implantation one week later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMR＜40 and immediately PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients whose IMR＜40 undergo immediately stent implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMR≥40 and immediately PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients whose IMR≥40 undergo immediately stent implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IMR≥40 and defer PCI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients whose IMR≥40 undergo anticoagulation and antiplatelet therapy for stent implantation one week later</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Index of microcirculatory resistance（IMR）</intervention_name>
    <description>IMR can be used to measure the microcirulatory resistance of coronary artery.It is not clear whether the IMR value could determine the time of PCI for STEMI patients.</description>
    <arm_group_label>IMR≥40 and defer PCI</arm_group_label>
    <arm_group_label>IMR≥40 and immediately PCI</arm_group_label>
    <arm_group_label>IMR＜40 and defer PCI</arm_group_label>
    <arm_group_label>IMR＜40 and immediately PCI</arm_group_label>
    <other_name>stent implantation immediately or defer</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old ≤ age ≤ 80 years old;

          -  Determine the diagnosis as STEMI, and the onset time is &lt;12h;

          -  The lesions of the offender are in situ lesions;

          -  Sign written informed consent.

        Exclusion Criteria:

          -  Hemodynamic instability;

          -  Coronary artery diameter stenosis ≤ 70% after thrombus aspiration catheter fails to
             pass or after thrombus aspiration;

          -  Left main disease;

          -  AMI is caused by surgery, trauma, gastrointestinal bleeding or PCI, or its
             complications;

          -  AMI occurs in patients who have been hospitalized for other reasons;

          -  The investigator judges that the patient has poor compliance and cannot complete the
             study as required;

          -  The patient's life expectancy is ≤ 12 months;

          -  heart transplant patients;

          -  Definite diagnosis of patients with tumors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing An Zhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chunmei Wang</last_name>
      <phone>+8613521901670</phone>
      <email>wangchunmei0214@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianping Li</last_name>
      <email>lijianping@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second hospital of hebei medical university</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xinshun Gu</last_name>
      <phone>+8613930139688</phone>
      <email>348220248@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Yu, MD,PhD</last_name>
      <phone>+8645186605180</phone>
      <email>yubodr@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bin Liu</last_name>
      <phone>+8613500810268</phone>
      <email>liubin3333@vip.sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated hospital of military medical university</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhijing Zhao</last_name>
      <phone>+8613772020951</phone>
      <email>zhaozhj@fmmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Chest Hospital</name>
      <address>
        <city>Tianjing</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liuyin Li</last_name>
      <phone>+8618920652283</phone>
      <email>liuyin2088@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yining Yang</last_name>
      <phone>+8613199860611</phone>
      <email>yangyn5126@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 15, 2018</study_first_submitted>
  <study_first_submitted_qc>June 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2018</study_first_posted>
  <last_update_submitted>May 8, 2019</last_update_submitted>
  <last_update_submitted_qc>May 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Yu Bo</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

